TCL-1B5 Inhibitors
Chemical inhibitors of TCL-1B5 operate through various mechanisms to impede the protein's function. Staurosporine, a potent kinase inhibitor, can inhibit a wide range of protein kinases, which likely includes those responsible for phosphorylating TCL-1B5. This action prevents the necessary post-translational modifications of TCL-1B5, leading to its functional inhibition. Wortmannin and LY294002, both inhibitors of PI3K, prevent the activation of TCL-1B5 involved pathways by inhibiting PI3K. This disruption leads to a blockade in downstream signaling required for the normal function of TCL-1B5. Similarly, Rapamycin, through its complex with FKBP12, inhibits mTOR, a central player in cell growth and metabolism pathways. The inhibition of mTOR by Rapamycin leads to reduced signaling, which is necessary for TCL-1B5's activity.
Moreover, U0126 and PD98059, by selectively inhibiting MEK1/2, prevent the activation of the ERK pathway, which is a crucial step in the signaling cascades involving TCL-1B5. The reduction in ERK activity due to these inhibitors leads to a consequent decrease in TCL-1B5 function. SP600125 and SB203580 target different components of the MAP kinase pathway, namely JNK and p38 MAP kinase, respectively. The inhibition of these kinases by SP600125 and SB203580 can suppress the signaling that regulates TCL-1B5 activity. PP2, which inhibits Src family kinases, prevents phosphorylation events necessary for TCL-1B5's function. Furthermore, Dasatinib, a broad inhibitor of Src family kinases and BCR-ABL, can disrupt TCL-1B5 involved signaling pathways, leading to functional inhibition. Lastly, Gefitinib and Erlotinib, both EGFR tyrosine kinase inhibitors, halt the signaling cascades that TCL-1B5 may be part of, thereby inhibiting the functional activity of TCL-1B5 by preventing necessary downstream signaling events.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can inhibit a broad range of protein kinases, which may include those directly phosphorylating TCL-1B5, leading to functional inhibition of TCL-1B5's activity due to prevention of its required post-translational modifications. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K, a kinase involved in signaling pathways that TCL-1B5 may function within. By inhibiting PI3K, downstream signaling required for the activity of TCL-1B5 is disrupted, resulting in functional inhibition of TCL-1B5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that can prevent activation of pathways involving TCL-1B5. By blocking PI3K, LY294002 inhibits downstream signaling that is necessary for TCL-1B5's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central protein in cell growth and metabolism pathways in which TCL-1B5 may be involved. Inhibition of mTOR by Rapamycin leads to reduced signaling necessary for TCL-1B5 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream regulators of the ERK pathway, a pathway that TCL-1B5 could be part of. By blocking MEK1/2, U0126 prevents the activation of ERK, thus inhibiting the signaling processes required for TCL-1B5's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is necessary for the ERK pathway activation. Since TCL-1B5 is involved in such pathways, inhibiting MEK with PD98059 leads to reduced ERK activity and consequently functional inhibition of TCL-1B5. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), potentially involved in pathways with TCL-1B5. Inhibition of JNK by SP600125 can lead to disruption of signaling necessary for TCL-1B5's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which may intersect with signaling pathways involving TCL-1B5. Inhibition of p38 MAP kinase by SB203580 can lead to the suppression of signaling required for the function of TCL-1B5. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits Src family kinases, which may phosphorylate substrates involved in TCL-1B5's signaling pathways. By inhibiting these kinases, PP2 disrupts the activity of TCL-1B5 by preventing necessary phosphorylation events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of Src family kinases and BCR-ABL. Through its inhibition of Src kinases, Dasatinib can disrupt signaling pathways involving TCL-1B5, leading to its functional inhibition. | ||||||